SPONSOR FEATURE EMERGENT BioSolutions Inc.: A Lodestone Amongst Pebbles—Addressing Public Health Through

AUTHORS Mark Schneider, MD, MPH, Emergent BioSolutions, Director of Clinical and Medical Affairs, Redwood City, Ca. Stephanie Campbell, Ph.D., Emergent BioSolutions, Director of Medical Sciences , 400 Professional Dr, Suite 400, Gaithersburg, MD 20879 Kelly Warfield, Ph.D., Emergent BioSolutions VP, Vaccines Research and Development, 400 Professional Dr, Suite 400, Gaithersburg, MD 20879

WHO IS EMERGENT That same year Emergent COVID-19 pandemic caused by Established in 1998, Emergent BioSolutions broadened its scope CUTTING EDGE the SARS-CoV-2 virus. BioSolutions built its 20-year of business into travel health with TECHNOLOGY FOR PUBLIC reputation on enhancing and the acquisition of PaxVax Inc. This HEALTH PREPAREDNESS TRAVEL HEALTH AND protecting the lives of the further strengthened Emergent’s TROPICAL MEDICINE community through the delivery of position within infectious diseases • 1800 Employees Infectious Diseases solutions for public health threats. and placed Emergent at the • 10 Marketed Products The number of people traveling Established from a foundation forefront of protecting the health • 19 Global Locations internationally continues to in manufacturing, Emergent has of travelers as they visit areas • 15+ Pipeline Products increase each year. Travelers may evolved into a globally recognized of endemic disease. Among the be at risk for contracting infectious leader in specialty and acquired products are 2 oral diseases. Travelers who become therapeutic technology and vaccines to help in the prevention ill experience disruptions to development. Emergent has been of travel-related bacterial their trip and may suffer serious providing the U.S. Government infections: Vaxchora® (Cholera complications or lasting side (USG) with a high quality and vaccine, Live, Oral) for the effects. Emergent BioSolutions reliable supply chain for medical prevention of cholera and Vivotif® aspires to give travelers peace countermeasure solutions. (Typhoid Vaccine Live Oral Ty21a) of mind by producing vaccines A testament to Emergent’s for the prevention of typhoid fever. to protect against the threats of ability to deliver public health grow and strengthen its poxvirus emerging and existing infectious threat solutions was evident SOLUTIONS and portfolios. diseases as they consider their through its partnership in 2012 Medical Countermeasures Emergent continues to partner travel health prior to traveling. with the Biomedical Advanced Emergent partnered with the with the USG and others to Emergent BioSolutions Research and Development USG to supply the nation’s address public health threats holds the license to the two Authority (BARDA), whereby only approved anthrax vaccine, to build its own robust pipeline FDA approved oral vaccines Emergent entered into a public- BioThrax® (Anthrax Vaccine against a variety of potential Vaxchora® and Vivotif®, to help private partnership to establish Adsorbed). Emergent has biodefense agents including the prevent cholera and typhoid the Center for Innovation in gradually grown from a one site, hemorrhagic fever viruses such as fever, respectively. In Europe, Advanced Development and one product company to become Lassa, Ebola and Marburg. Vaxchora® is centrally approved Manufacturing (CIADM). The a leader in providing medical by the European Commission CIADM facilitates advanced countermeasures to the USG and POLYCLONAL while Vivotif® is approved by development of chemical, other international partners. Hyperimmune Platform 18 national health authorities. biological, radiological, and With the purchase of Cangene Hyperimmunes work through Additionally, Emergent has a nuclear (CBRN) medical Corporation in 2014, a number passive immunity to provide strong pipeline of candidate countermeasures for public health of hyperimmune products were immediate protection to people, vaccines, including threats and ensures domestic added to Emergent’s portfolio including vulnerable populations. virus-like particle (CHIKV VLP) manufacturing surge capacity to to combat anthrax (Anthrasil® Emergent has experience and Shigella-ETEC vaccines. address the USG’s preparedness (Anthax Immune Globulin with developing and licensing Emergent BioSolutions priorities and needs. Intravenous (human)) , botulism hyperimmune products. It continues to leverage its In 2018, Emergent BioSolutions (BAT® [Botulism Antitoxin has two well-established expertise in vaccine development, placed itself on center stage in the Heptavalent ) and vaccinia vaccine hyperimmune platforms (human hyperimmune platform and opioid crisis through its purchase side effects (CNJ-016® [Vaccinia and equine) that support several diverse manufacturing and of ADAPT PHARMA. This Immune Globulin Intravenous ). FDA-licensed products targeted technologic capabilities to investment brought NARCAN® In 2017, Emergent added to specific indications. accomplish its overarching ( HCL) Nasal Spray, ACAM2000® Smallpox (Vaccinia) Notably, both of Emergent’s corporate strategic goal to furthering Emergent’s sustained Vaccine, and raxibacumab hyperimmune platforms are protect and enhance one billion commitment to public health. (anthrax monoclonal ) to being leveraged to respond to the lives by 2030.

Sponsor retains sole responsibility for content SPONSOR FEATURE

Sponsor retains sole responsibility for content